Melanotan I vs Melanotan II: Preclinical Research Differences (2026)

Melanotan I (MT-1) is a linear peptide selective for the MC1R receptor, whereas Melanotan II (MT-2) is a cyclic peptide that binds non-selectively across multiple melanocortin receptors^[1][2][3][4]. In preclinical laboratory models, the cyclic MT-2 peptide demonstrates a broader melanocortin receptor affinity and distinct molecular weight compared to the linear MT-1 compound^[1][5]. Researchers investigating melanocortin pathways must understand how these structural differences dictate receptor engagement and handling protocols in vitro.

CRITICAL COMPLIANCE NOTICE: Both Melanotan I and Melanotan II are experimental compounds designated strictly for laboratory research use only (RUO). These peptides are absolutely not for human consumption, medical, veterinary, or cosmetic use. The information provided is strictly for preclinical investigation and laboratory methodology.

This comparative analysis details the structural profiles, receptor binding affinities, molecular weights, and strict laboratory handling guidelines for MT-1 and MT-2. By examining the linear versus cyclic architecture, investigators can accurately select the appropriate compound for their specific melanocortin receptor assays.

What is the difference between Melanotan I and Melanotan II?

Melanotan I (MT-1) is a linear 13-amino-acid peptide, whereas Melanotan II (MT-2) is a short, cyclic 7-amino-acid lactam-bridged peptide^[1][3][5]. This fundamental architectural difference directly dictates their distinct receptor selectivity and stability in preclinical models^[6][4]. Both Melanotan I and Melanotan II are strictly designated for laboratory research use only (RUO) and are absolutely not for human consumption, medical, or cosmetic use^[7][8].

The linear structure of MT-1, also known as afamelanotide in certain experimental contexts, features an extended backbone^[3][9]. It is a 13-residue analogue of alpha-melanocyte-stimulating hormone (α-MSH) with specific amino acid substitutions, including norleucine and D-phenylalanine, designed to enhance stability while preserving its linear geometry^[5][9]. This extended conformation maintains a high specificity for a single receptor target in laboratory assays^[1][6].

Conversely, the MT-2 research peptide utilizes a constrained cyclic conformation^[4]. The cyclization is achieved via a lactam linkage between the side-chain carboxyl group of aspartic acid and the side-chain amino group of lysine^[3][5]. This lactam bridge locks the active pharmacophore into a rigid beta-turn structure^[1][4]. While this cyclization increases overall binding potency and resistance to proteolytic degradation, it significantly reduces receptor selectivity compared to the linear MT-1 compound^[1][5].

In laboratory environments, investigators must account for these structural variations when designing experiments. The linear MT-1 peptide is typically selected when high receptor specificity is required to isolate specific signaling pathways^[2][9]. The cyclic MT-2 peptide is utilized when broader, non-selective melanocortin receptor activation is the experimental objective^[4][10]. Researchers sourcing these research compounds must strictly adhere to in vitro and animal model protocols, as neither peptide is approved for any human application^[11][12].

Which receptors do MT-1 and MT-2 target in laboratory research?

In preclinical laboratory models, the cyclic MT-2 peptide demonstrates a broader melanocortin receptor affinity and distinct molecular weight compared to the linear MT-1 compound^[1][4]. MT-1 selectively targets MC1R, whereas MT-2 exhibits binding affinity across MC1R, MC3R, MC4R, and MC5R receptors^[1][2][13].

The receptor pharmacology of these compounds is heavily influenced by their linear and cyclic structures^[3][5]. In transfected cell assays, the linear MT-1 peptide demonstrates high selectivity for the melanocortin-1 receptor (MC1R), with an observed effective concentration (EC50) typically in the 0.1 to 0.5 nM range^[1]. Its activity at other receptors, such as MC3R and MC4R, is approximately 50 to 100 times weaker, making it an ideal tool for isolating MC1R-mediated pathways in vitro^[1][6].

The cyclic MT-2 peptide functions as a non-selective melanocortin receptor agonist^[4][10]. The constrained lactam bridge optimizes the peptide for binding across multiple subtypes. Laboratory binding data indicate that MT-2 engages MC1R at approximately 0.3 nM, MC3R at 2.1 nM, MC4R at 1.1 nM, and MC5R at 2.8 nM^[1]. Consequently, any experimental concentration sufficient to activate MC1R will also substantially activate the other receptor subtypes^[1][4].

Research Parameter	Melanotan I (MT-1)	Melanotan II (MT-2)
Structure	Linear (13 amino acids)[1][5]	Cyclic lactam bridge (7 amino acids)[3][4]
Primary Receptors	Selective for MC1R[1][6]	Non-selective (MC1R, MC3R, MC4R, MC5R)[1][13]
Molecular Weight	~1646.8 g/mol[14]	~1024.2 g/mol[14]
Preclinical Half-Life	~30 minutes to 2 hours[1]	~33 to 40 minutes (IV models)[4]

Researchers investigating the MT-1 peptide or MT-2 must carefully select their compound based on these binding profiles. The distinct molecular weights – approximately 1646.8 g/mol for MT-1 versus 1024.2 g/mol for MT-2 – also require precise molar calculations during laboratory reconstitution^[14]. Both compounds remain strictly confined to non-human investigational use^[7].

What are the preclinical research parameters and RUO guidelines for MT-1 and MT-2?

These compounds are restricted to laboratory investigation to study melanocortin pathways and are not approved for human or veterinary administration^[11][12]. Researchers must handle both peptides under strict laboratory protocols, maintaining storage at recommended sub-zero temperatures to preserve structural integrity^[4][15].

The regulatory framework for these compounds is absolute. Melanotan I and Melanotan II are experimental agonists supplied exclusively for research use only (RUO)^[7][16]. They are completely unregulated for consumer use, and no regulatory body has approved either compound for human administration or therapeutic treatment^[11][8]. Laboratories must enforce strict chemical hygiene protocols, utilizing appropriate personal protective equipment when handling the lyophilized powders^[17].

Preserving the structural integrity of these peptides requires rigorous environmental control. Both structures are susceptible to degradation if exposed to elevated temperatures, moisture, or light^[4][18].

• Sub-Zero Storage: Lyophilized MT-1 and MT-2 must be stored frozen at or below -20°C for long-term stability^[4][7]. Storage at 4°C significantly increases degradation rates^[4].
• Moisture Protection: Vials must remain strictly desiccated. Moisture promotes hydrolysis and peptide bond degradation^[4][18].
• Light Avoidance: UV and visible light degrade photo-labile residues. Researchers must utilize amber vials or opaque packaging^[4][15].
• Reconstitution Protocols: Solvents such as bacteriostatic water are utilized for laboratory stock solutions. Reconstituted solutions should be stored between 2°C and 8°C for short-term use, avoiding repeated freeze-thaw cycles^[4][15].

By adhering to these laboratory storage guidelines, investigators ensure accurate data while maintaining absolute compliance. To source compliant compounds for your laboratory, contact Nautilus Peptides today.

Frequently Asked Questions

What is the difference between Melanotan I and Melanotan II?

Melanotan I (MT-1) is a linear 13-amino-acid peptide that selectively targets the MC1R receptor in laboratory models^[1][5]. Melanotan II (MT-2) is a cyclic 7-amino-acid peptide with a lactam bridge that acts as a non-selective agonist across multiple melanocortin receptors^[3][4].

Which receptors do MT-1 and MT-2 target in laboratory research?

In preclinical assays, the linear MT-1 peptide selectively binds to the melanocortin-1 receptor (MC1R)^[1][6]. The cyclic MT-2 peptide demonstrates a broader binding affinity, substantially activating MC1R, MC3R, MC4R, and MC5R^[1][13].

What is the molecular weight and half-life of MT-2?

The molecular weight of the cyclic MT-2 peptide is approximately 1024.2 g/mol^[14]. In preclinical intravenous animal models, it exhibits a plasma half-life of approximately 33 to 40 minutes^[4].

Are MT-1 and MT-2 peptides for human use?

No. Both Melanotan I and Melanotan II are strictly designated for laboratory research use only (RUO)^[7][8]. They are experimental compounds not approved by any regulatory body for human consumption, medical treatment, veterinary administration, or cosmetic use^[11][12].

References

1. Melanotan 1 Vs Melanotan 2 Research – Maple Research Labs. https://mapleresearchlabs.com/peptide-research/melanotan-i-vs-melanotan-ii-melanocortin-receptor-pharmacology-research-comparison/ (2026-05-08)
2. Melanotan II (MT-II): A Non-Selective Melanocortin Receptor Agonist …. https://superpower.com/guides/melanotan-2 (2026-04-18)
3. Melanotan 1 vs. Melanotan 2 | A Comprehensive Comparison. https://www.peptides.org/melanotan-1-vs-melanotan-2/ (2024-05-05)
4. Melanotan-2 (MT-II): Comprehensive Research Monograph. https://peptidebiologix.com/melanotan-2 (2026-06-17)
5. What is melanotan II? – Creative Peptides. https://www.creative-peptides.com/resources/what-is-melanotan-ii-peptide.html (2025-01-27)
6. Melanotan: A Family of Synthetic Melanocortin Receptor Agonist …. https://superpower.com/guides/melanotan (2026-04-18)
7. [PDF] Melanotan-II – Cell Sciences. https://www.cellsciences.com/PDF/CRM126.pdf (2026-03-30)
8. Melanotan injections are sold illegally and possibly unsafe. https://news.cancerresearchuk.org/2009/01/28/melanotan-injections-are-illegal-and-possibly-unsafe/ (2009-01-28)
9. What is the difference between Melanotan-1 and Melanotan-2?. https://www.chemicalbook.com/article/what-is-the-difference-between-melanotan-1-and-melanotan-2.htm (2024-12-06)
10. Melanotan II – an overview | ScienceDirect Topics. https://www.sciencedirect.com/topics/medicine-and-dentistry/melanotan-ii (2025-09-27)
11. Melanotan II – DermNet. https://dermnetnz.org/topics/melanotan-ii (2023-10-26)
12. What is Melanotan-II – the drug that the TGA urges consumers to …. https://www.unsw.edu.au/newsroom/news/2023/01/what-is-melanotan-ii—the-drug-that-the-tga-urges-consumers-to- (2023-01-30)
13. Melanotan II – Wikipedia. https://en.wikipedia.org/wiki/Melanotan_II (2006-03-20)
14. Melanotan 1 vs Melanotan 2 – GuideChem. https://www.guidechem.com/guideview/phar/melanotan-1-vs-melanotan-2.html (2024-12-17)
15. [PDF] Application Notes and Protocols for Lyophilized Melanotan-II in …. https://www.benchchem.com/pdf/Application_Notes_and_Protocols_for_Lyophilized_Melanotan_II_in_Research.pdf (2025-12-22)
16. [PDF] Melanotan-II: A Comparative Analysis of its Efficacy in Preclinical …. https://www.benchchem.com/pdf/Melanotan_II_A_Comparative_Analysis_of_its_Efficacy_in_Preclinical_Disease_Models.pdf (2025-12-15)
17. [PDF] SAFETY DATA SHEET – Fisher Scientific. https://www.fishersci.com/store/msds?partNumber=AAJ65115MCR&productDescription=MELANOTAN+II+1MG&vendorId=VN00024248&countryCode=US&language=en (2025-09-29)
18. How Does Temperature Affect Melanotan 2 Powder Stability?. https://www.bloomtechz.com/info/how-does-temperature-affect-melanotan-2-powder-102868638.html (2025-05-06)